Clinical Study

Real-world results of definitive chemoradiation in carcinoma oesophagus: can SCOPE1 results be replicated outside trial setting?

24 Aug 2021
Tapesh Bhattacharyya, Vishnu Harilal, Rohit Sashidharan, Indranil Mallick, Moses Arunsingh, Santam Chakraborty, Rimpa Basu Achari, Sanjoy Chatterjee

Background: Definite concurrent chemoradiation is the standard of care for locally advanced unresectable oesophageal cancers. However, heterogeneity exists in the practice of concurrent chemoradiation approaches. Here we describe the efficacy and toxicities of the standard arm of SCOPE1 protocol implemented at our institute.

Methods: Treatment records of 36 patients with unresectable oesophageal cancers treated with concurrent chemoradiation between January 2015 and June 2019 were audited. Treatment was based on the standard arm of SCOPE1 protocol (neoadjuvant and concurrent platinum and capecitabine with external beam radiation to a dose of 50 Gy/25 fractions/5 weeks). The electronic hospital information system and oncology information system were queried to obtain information on patient characteristics and treatment delivery patterns.

Results: Out of 36 patients, 35 had squamous cell carcinomas. 25% of the patients (9/36) were 70 years or older. 66.7% of patients (24/36) had T4 disease, and 16 (44.4%) had N2-N3 nodal disease at presentation. A total of 30 patients (83.3%) could not undergo surgery because of the location and locoregional extent of the disease. The median follow-up of the entire cohort and the surviving patients was 10 months (range 3–51 months) and 13 months (range 4–51 months), respectively. The median overall survival (OS) of the entire cohort was 28 months. The 2-year local progression-free survival and OS were 71.2% (95% CI: 48.5%–85.3%) and 57.4% (95%CI: 29.6%–77.6%), respectively. Commonly observed acute Grade 3 toxicities were dysphagia (22.2%) and thrombocytopenia (19.4%).

Conclusion: The outcomes of the SCOPE1 protocol have been validated for the first time in a different geographical, racial and ethnic population. Implementation of the standard arm of SCOPE1 protocol is feasible in our setting with acceptable adverse effects and good treatment compliance. Results are comparable to the results of the published trial.

Related Articles

Mauro Daniel Spina Donadio, Dirce Maria Carraro, Giovana Tardin Torrezan, Celso Abdon Lopes de Mello
Tiago Cordeiro Felismino, Felipe Marcio Araujo Oliveira, Camilla Albina Zanco Fogassa, Silvia Nardozza Santerini, Victor Hugo Fonseca de Jesus, Rachel Simões Pimenta Riechelmann, Felipe José Fernandez Coimbra, Celso Abdon Lopes Mello
Dabna Hellen Tomim, Bruna Eloise Lenhani, Luciana de Alcantara Nogueira, Tatiele Naiara Vogt, Leonel dos Santos Silva, Maria de Fátima Mantovani, Paulo Ricardo Bittencourt Guimarães, Luciana Puchalski Kalinke
Soumitra Shankar Datta, Soumita Ghose, Manisha Ghosh, Amruta Jain, Sumedha Mandal, Sayan Chakraborty, Carlo Caduff
Foziya Mohammed Hussien, Anissa Mohammed Hassen, Zinet Abegaz Asfaw, Aragaw Yimer Ahmed, Yeshimebet Ali Dawed, Ahmed Hussien Asfaw, Erkihun Tadesse Amsalu, Hamid Yimam Hassen